Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 688

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 688
---
───────────────────────────────────────────────────────
  Weighted average number of outstanding ordinary shares in issue                                855,351,683      849,654,296      847,143,540  
  Net income/(loss) attributable to the Company (US$ ’ 000)                                           37,729          100,780       ( 360,835)  
  Basic earnings/(losses) per share attributable to the Company (US$ per share)                         0.04             0.12          ( 0.43)  

F-49

Table of Contents

(ii) Diluted earnings/(losses) per share
─────────────────────────────────────────────────
Diluted earnings/(losses) per share is calculated by dividing net income/(loss) attributable to the Company by the weighted average number of outstanding ordinary shares in issue and dilutive ordinary share equivalents outstanding during the year. Dilutive ordinary share equivalents include shares issuable upon the exercise or settlement of share options and LTIP awards issued by the Company using the treasury stock method.
Year Ended December 31,
2024 2023 2022
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Weighted average number of outstanding ordinary shares in issue 855,351,683 849,654,296 847,143,540
Effect of share options and LTIP awards 17,477,446 19,542,052 - 
Weighted average number of outstanding ordinary shares in issue and dilutive ordinary share equivalents outstanding 872,829,129 869,196,348 847,143,540
Net income/(loss) attributable to the Company (US$ ’ 000) 37,729 100,780 ( 360,835)
Diluted earnings/(losses) per share attributable to the Company (US$ per share) 0.04 0.12 ( 0.43)
For the year ended December 31, 2022, the share options and LTIP awards issued by the Company were not included in the calculation of diluted losses per share because of their anti-dilutive effect. 26. Segment Reporting
The Group’s operating segments are as follows:
(i) Oncology/Immunology: focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Oncology/Immunology i...
(a